Entry Name PD-L1 expression and PD-1 checkpoint pathway in cancer - Felis catus (domestic cat)
Description Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.
Class Human Diseases; Cancer: overviewBRITE hierarchy
Pathway map fca05235 PD-L1 expression and PD-1 checkpoint pathway in cancer
Organism Felis catus (domestic cat) [GN:
fca ]
Gene 100142683 NFKB1; nuclear factor NF-kappa-B p105 subunit isoform X1 [KO:K02580 ]
100271864 PIK3R1; phosphatidylinositol 3-kinase regulatory subunit alpha isoform X3 [KO:K02649 ]
101080520 NFATC2; nuclear factor of activated T-cells, cytoplasmic 2 isoform X1 [KO:K17332 ]
101080604 CD247; T-cell surface glycoprotein CD3 zeta chain isoform X1 [KO:K06453 ]
101082971 BATF3; basic leucine zipper transcriptional factor ATF-like 3 isoform X3 [KO:K09034 ]
101083107 CD3D; T-cell surface glycoprotein CD3 delta chain isoform X1 [KO:K06450 ]
101083728 NFATC3; nuclear factor of activated T-cells, cytoplasmic 3 isoform X3 [KO:K17333 ]
101084561 STAT1; signal transducer and activator of transcription 1-alpha/beta [KO:K11220 ]
101086926 PPP3CB; serine/threonine-protein phosphatase 2B catalytic subunit beta isoform isoform X1 [KO:K04348 ] [EC:3.1.3.16 ]
101087092 MYD88; myeloid differentiation primary response protein MyD88 [KO:K04729 ]
101088688 TIRAP; toll/interleukin-1 receptor domain-containing adapter protein isoform X2 [KO:K05403 ]
101091892 PIK3CB; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform [KO:K00922 ] [EC:2.7.1.153 ]
101092925 PLCG1; 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 isoform X1 [KO:K01116 ] [EC:3.1.4.11 ]
101093097 PPP3CC; serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform isoform X2 [KO:K04348 ] [EC:3.1.3.16 ]
101093319 LAT; linker for activation of T-cells family member 1 isoform X1 [KO:K07362 ]
101093586 PIK3R2; phosphatidylinositol 3-kinase regulatory subunit beta [KO:K02649 ]
101094274 PIK3CD; LOW QUALITY PROTEIN: phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform [KO:K00922 ] [EC:2.7.1.153 ]
101094586 EML4; echinoderm microtubule-associated protein-like 4 isoform X1 [KO:K15420 ]
101095682 BATF2; basic leucine zipper transcriptional factor ATF-like 2 isoform X1 [KO:K09034 ]
101095698 STAT3; signal transducer and activator of transcription 3 isoform X1 [KO:K04692 ]
101097144 PPP3CA; serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform isoform X1 [KO:K04348 ] [EC:3.1.3.16 ]
101097413 PIK3CA; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [KO:K00922 ] [EC:2.7.1.153 ]
101097987 BATF; basic leucine zipper transcriptional factor ATF-like [KO:K09034 ]
101099259 NFKBIB; LOW QUALITY PROTEIN: NF-kappa-B inhibitor beta [KO:K02581 ]
101101259 NFATC1; nuclear factor of activated T-cells, cytoplasmic 1 isoform X2 [KO:K04446 ]
493775 CD4; T-cell surface glycoprotein CD4 precursor [KO:K06454 ]
493802 CD28; T-cell-specific surface glycoprotein CD28 precursor [KO:K06470 ]
493936 CD3E; T-cell surface glycoprotein CD3 epsilon chain precursor [KO:K06451 ]
493978 EGF; pro-epidermal growth factor precursor [KO:K04357 ]
Compound C01245 D-myo-Inositol 1,4,5-trisphosphate
C05981 Phosphatidylinositol-3,4,5-trisphosphate
Reference Authors Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ
Title PD-L1.
Journal Reference Authors Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X
Title A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Journal Reference Authors Wang Y, Wang H, Yao H, Li C, Fang JY, Xu J
Title Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion.
Journal Reference Authors Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z
Title Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
Journal Reference Authors Bardhan K, Anagnostou T, Boussiotis VA
Title The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.
Journal Reference Authors Shi Y
Title Regulatory mechanisms of PD-L1 expression in cancer cells.
Journal Reference Authors Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T
Title Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
Journal Reference Authors Chen J, Jiang CC, Jin L, Zhang XD
Title Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Journal Reference Authors Glodde N, Holzel M
Title RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion.
Journal Reference Authors Ritprajak P, Azuma M
Title Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.
Journal Reference Authors Nirschl CJ, Drake CG
Title Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
Journal Reference Authors Saeidi A, Zandi K, Cheok YY, Saeidi H, Wong WF, Lee CYQ, Cheong HC, Yong YK, Larsson M, Shankar EM
Title T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses.
Journal Reference Authors Sharpe AH, Pauken KE
Title The diverse functions of the PD1 inhibitory pathway.
Journal Reference Authors Boussiotis VA
Title Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
Journal Reference Authors Arasanz H, Gato-Canas M, Zuazo M, Ibanez-Vea M, Breckpot K, Kochan G, Escors D
Title PD1 signal transduction pathways in T cells.
Journal Reference Authors Zuazo M, Gato-Canas M, Llorente N, Ibanez-Vea M, Arasanz H, Kochan G, Escors D
Title Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.
Journal Reference Authors Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA
Title PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.
Journal Reference Authors Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X
Title New immunotherapies targeting the PD-1 pathway.
Journal Reference Authors Ok CY, Young KH
Title Targeting the programmed death-1 pathway in lymphoid neoplasms.
Journal Related fca04620 Toll-like receptor signaling pathway
fca04660 T cell receptor signaling pathway
KO pathway
